American Diabetes Association
Browse
DOCUMENT
REV1_Supplementary_information_Ofori_et_al_20210928.pdf (1.57 MB)
DOCUMENT
Human_Islet_Checklist_1.pdf (202.96 kB)
DOCUMENT
Human_Islet_Checklist_2.pdf (202.63 kB)
DOCUMENT
Human_Islet_Checklist_3.pdf (202.83 kB)
DOCUMENT
Human_Islet_Checklist_4.pdf (203.31 kB)
DOCUMENT
Human_Islet_Checklist_5.pdf (201.4 kB)
1/0
6 files

Human Islet MicroRNA-200c is Elevated in Type 2 Diabetes and Targets the Transcription Factor ETV5 to Reduce Insulin Secretion

figure
posted on 2021-11-15, 17:42 authored by Jones K. Ofori, Alexandros Karagiannopoulos, Mototsugu Nagao, Efraim Westholm, Shaima Ramadan, Anna Wendt, Jonathan LS Esguerra, Lena Eliasson
MicroRNAs (miRNAs) are part of deregulated insulin secretion in type 2 diabetes (T2D) development. Rodent models have suggested miR-200c to be involved, but the role and potential as therapeutic target of this miRNA in human islets is not clear. Here we report increased expression of miR-200c in islets from T2D as compared with non-diabetic (ND) donors and display results showing reduced glucose-stimulated insulin secretion in EndoC-βH1 cells overexpressing miR-200c. We identify transcription factor ETV5 as the top rank target of miR-200c in human islets using TargetScan in combination with Pearson correlation analysis of miR-200c and mRNA expression data from the same human donors. Among other targets were JAZF1, as earlier shown in miR-200 knockout mice. Accordingly, linear model analysis of ETV5 and JAZF1 gene expression showed reduced expression of both genes in islets from human T2D donors. Western blot analysis confirmed the reduced expression of ETV5 on protein level in EndoC-βH1 cells overexpressing miR-200c and Luciferase assay validated ETV5 as a direct target of miR-200c. Finally, LNA knockdown of miR-200c (LNA200c) increased glucose-stimulated insulin secretion in islets from T2D donors ~3-fold. Our data reveal a vital role of the miR-200c-ETV5 axis in beta cell dysfunction and pathophysiology of T2D.

Funding

This work is supported by a grant from the Swedish Foundation for Strategic Research (IRC-LUDC) and the Swedish Research Council through an SRA grant SFO-EXODIAB. L.E. has support for this project through project grants from the Swedish Research Council, Region Skåne-ALF, the Swedish Diabetes Foundation, the Diabetes Wellness Network Sweden and EFSD-MSD. J.O is supported by the Royal Physiographic Society of Lund through Birgit and Hellmuth Hertz Foundation.

History